| 49115-9 |
Thiamine.free |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Thiamine.free [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHEM |
|
49115-9 |
|
|
|
|
Both |
|
|
|
0 |
Vit B1 free Bld-mCnc |
|
|
|
N |
|
Blood; c106; c238; Chemistry; FR; Level; Mass concentration; Non-protein bound; Point in time; QNT; Quan; Quant; Quantitative; Random; Vit B1; Vit B-1; Vit B1 free; Vitamin B1; Vitamin B-1; WB; Whole blood |
2.73 |
2.21 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 49116-7 |
Trichosporon sp DNA |
ACnc |
Ser |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Trichosporon sp DNA [Units/volume] in Serum by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49116-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
Trichosporon sp DNA Ser NAA+probe-aCnc |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Arbitrary concentration; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; SDA; Serum; species; spp; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.21 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 49117-5 |
Norovirus Ag |
PrThr |
Stool |
Pt |
Ord |
|
|
ACTIVE |
Norovirus Ag [Presence] in Stool |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49117-5 |
|
|
|
|
Both |
|
|
|
0 |
Norovirus Ag Stl Ql |
|
|
|
N |
|
Antigen; Antigens; Bowel movement; Faecal; Faeces; Fecal; Feces; Human Calcivirus; ID; Infectious Disease; InfectiousDisease; Microbiology; Norwalk virus; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Stl; Stool = Fecal |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49118-3 |
Views^W radionuclide IV |
Find |
XXX |
Pt |
Doc |
NM |
|
ACTIVE |
NM Unspecified body region Views |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
49118-3 |
|
NM |
|
|
Both |
|
|
|
0 |
NM Views W RNC IV |
|
|
|
N |
|
Document; Films; Finding; Findings; Imaging; Misc; Miscellaneous; Other; Point in time; Rad; RADIOLOGY; Random; RN; RNC; Scan; Spec; To be specified in another part of the message; Unspecified; View; VWS; W RNC IV |
2.64 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The scale has been changed from "Nar" to "Doc" to fit with the CDA model.; Method of "Radnuc" was changed to "NM". The LOINC/RadLex Committee agreed to use a subset of the two-letter DICOM modality codes as the primary modality identifier. |
0 |
| 49119-1 |
Monosaccharides.sulfated |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Monosaccharides.sulfated [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
NORMAL |
|
|
|
|
|
CHEM |
|
49119-1 |
|
|
|
|
Both |
|
|
|
0 |
Monosaccharides.sulfated Ur Ql |
|
|
|
N |
|
Chemistry; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.56 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4912-2 |
HLA-Dw6 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-Dw6 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4912-2 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-Dw6 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49120-9 |
Immunodeficiency follow-up panel |
- |
XXX |
Pt |
- |
Flow cytometry |
|
ACTIVE |
Immunodeficiency follow-up panel - Specimen by Flow cytometry (FC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CELLMARK |
|
49120-9 |
|
Flow cytometry |
|
|
Order |
|
|
|
0 |
Immunodeficiency follow-up Pnl Spec FC |
|
|
|
N |
|
CD4 panel; CELL MARKERS; Dynamic; FC; Immunodeficiency follow-up Pnl; Misc; Miscellaneous; Other; Pan; PANEL.CELLMARK; Panl; Pnl; Point in time; Random; Spec; To be specified in another part of the message; UniversalLabOrders; Unspecified |
2.73 |
2.21 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 49121-7 |
Erythrocyte inclusion bodies |
Prid |
Bld |
Pt |
Nom |
|
|
ACTIVE |
Erythrocyte inclusion bodies [Identifier] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
Possible answers include Heinz bodies, Cabot rings, Howell Jolly bodies, Pappenheimer bodies or parasites(ex: malarial species). |
|
|
|
|
|
HEM/BC |
|
49121-7 |
|
|
|
|
Observation |
|
|
|
0 |
RBC inclusions Bld |
|
|
|
N |
|
Blood; bod; Body; Discocyte; Erc; Erythrocytes; HEMATOLOGY/CELL COUNTS; Identity or presence; Nominal; Point in time; Random; RBC; RBC inclusions; Red blood cell; Red blood cells; Red blood corpuscle; Red blood corpusles; Red cell; Red cells; WB; Whole blood |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49122-5 |
Anaplasma sp |
Prid |
XXX |
Pt |
Nom |
Sequencing |
|
ACTIVE |
Anaplasma sp identified in Specimen by Sequencing |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49122-5 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
Anaplasma Spec Seq |
|
|
|
N |
|
Bovine anaplasmosis; high-throughput sequencing; HTS; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Next generation sequencing; NGS; Nominal; Other; Point in time; Random; Spec; species; spp; To be specified in another part of the message; Unspecified |
2.78 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; Previous Releases: Changed method from Amplification/Sequencing because Amplification always occurs before sequencing |
0 |
| 49123-3 |
Bartonella sp |
Prid |
XXX |
Pt |
Nom |
Sequencing |
|
ACTIVE |
Bartonella sp identified in Specimen by Sequencing |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49123-3 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
Bartonella Spec Seq |
|
|
|
N |
|
high-throughput sequencing; HTS; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Next generation sequencing; NGS; Nominal; Other; Point in time; Random; Rochalimaea species; Spec; species; spp; To be specified in another part of the message; Unspecified |
2.79 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; Previous Releases: Changed method from Amplification/Sequencing because Amplification always occurs before sequencing |
0 |
| 49124-1 |
Coxiella burnetii |
Prid |
XXX |
Pt |
Nom |
Sequencing |
|
ACTIVE |
Coxiella burnetii identified in Specimen by Sequencing |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49124-1 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
C burnet Spec Seq |
|
|
|
N |
|
C burnet; C burnetii; Coxiella burnettii; high-throughput sequencing; HTS; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Next generation sequencing; NGS; Nominal; Other; Point in time; Q fev; Q fever; Qfever; Random; Spec; To be specified in another part of the message; Unspecified |
2.78 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; Previous Releases: Changed method from Amplification/Sequencing because Amplification always occurs before sequencing |
0 |
| 49125-8 |
Ehrlichia sp |
Prid |
XXX |
Pt |
Nom |
Sequencing |
|
ACTIVE |
Ehrlichia sp identified in Specimen by Sequencing |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49125-8 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
Ehrlichia Spec Seq |
|
|
|
N |
|
high-throughput sequencing; HTS; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Next generation sequencing; NGS; Nominal; Other; Point in time; Random; Spec; species; spp; To be specified in another part of the message; Unspecified |
2.79 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; Previous Releases: Changed method from Amplification/Sequencing because Amplification always occurs before sequencing |
0 |
| 49126-6 |
Orientia tsutsugamushi |
Prid |
XXX |
Pt |
Nom |
Sequencing |
|
ACTIVE |
Orientia tsutsugamushi identified in Specimen by Sequencing |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49126-6 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
O tsut Spec Seq |
|
|
|
N |
|
high-throughput sequencing; HTS; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Next generation sequencing; NGS; Nominal; O tsut; O tsutsugamushi; Oriental scrub typhus; Other; Point in time; R orienta; R tsutsugamuchi; R tsutsugamushi; Random; Rickettsia orienta; Rickettsia tsutsugamuchi; Rickettsia tsutsugamushi; Scrub typhus; Spec; To be specified in another part of the message; Unspecified |
2.78 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; Previous Releases: Changed method from Amplification/Sequencing because Amplification always occurs before sequencing |
0 |
| 49127-4 |
Rickettsia sp |
Prid |
XXX |
Pt |
Nom |
Sequencing |
|
ACTIVE |
Rickettsia sp identified in Specimen by Sequencing |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49127-4 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
Rickettsia Spec Seq |
|
|
|
N |
|
high-throughput sequencing; HTS; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Next generation sequencing; NGS; Nominal; Other; Point in time; Random; Ricket; Rickettsial; Spec; species; spp; To be specified in another part of the message; Unspecified |
2.79 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; Previous Releases: Changed method from Amplification/Sequencing because Amplification always occurs before sequencing |
0 |
| 49128-2 |
Rickettsia typhus group |
Prid |
XXX |
Pt |
Nom |
Sequencing |
|
ACTIVE |
Rickettsia typhus group identified in Specimen by Sequencing |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49128-2 |
|
Sequencing |
|
|
Both |
|
|
|
0 |
Rick Typhus Spec Seq |
|
|
|
N |
|
high-throughput sequencing; HTS; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Next generation sequencing; NGS; Nominal; Other; Point in time; Random; Rick Typhus; Ricket; Rickettsial; Spec; To be specified in another part of the message; Typh; Typhus; Unspecified |
2.78 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; Previous Releases: Changed method from Amplification/Sequencing because Amplification always occurs before sequencing |
0 |
| 49129-0 |
Creatine kinase.MiMi/Creatine kinase.total |
CFr |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatine kinase.MiMi/Creatine kinase.total in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
% |
12%. |
|
|
|
|
|
CHEM |
|
49129-0 |
|
|
|
|
Observation |
|
|
|
0 |
CK MiMi CFr SerPl |
|
|
|
N |
|
Catalytic Fraction; Chemistry; CK; CK MiMi; Ckmit; CPK; Creatine phosphokinase; Mitochondrial Creatine Kinase; Percent; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tot; Totl |
2.34 |
2.21 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 4913-0 |
HLA-Dw6 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-Dw6 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4913-0 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-Dw6 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49130-8 |
Cholesterol.in HDL |
MCnc |
Ser/Plas |
Pt |
Qn |
Electrophoresis |
|
ACTIVE |
Cholesterol in HDL [Mass/volume] in Serum or Plasma by Electrophoresis |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
HDL-Cholesterol (Elpho) 70 mg/dl. |
|
|
|
|
|
CHEM |
|
49130-8 |
|
Electrophoresis |
|
|
Both |
|
|
|
0 |
HDLc SerPl Elph-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Elec; Elect; Electr; Electro; Electrophhrs; Electrophrs; Elp; Elph; Ep; HDLc; HDL-C; Heart Disease; High density lipoprotein cholesterols; Level; Lipid; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; TCHHDL |
2.73 |
2.21 |
|
|
|
|
|
|
|
mg/dL |
|
|
Changed Order_Obs from 'Observation Only' to 'Both' to fit current order use cases. |
0 |
| 49131-6 |
Chylomicrons/Lipoprotein.total |
MFr |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Chylomicrons/total Lipoprotein in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
% |
Chylomicrons 32% of lipoproteins. |
|
|
|
|
|
CHEM |
|
49131-6 |
|
|
|
|
Observation |
|
|
|
0 |
Chylo MFr SerPl |
|
|
|
N |
|
Chemistry; Chylomicron; Lip; Lipoprot; Lipoproteins; LP; Mass Fraction; Percent; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tot; Totl; ULDL; Ultra low density lipoproteins |
2.73 |
2.21 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 49132-4 |
Cholesterol.in LDL |
MCnc |
Ser/Plas |
Pt |
Qn |
Electrophoresis |
|
ACTIVE |
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Electrophoresis |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
LDL-cholesterol (Elpho) is 200 mg/dl. |
|
|
|
|
|
CHEM |
|
49132-4 |
|
Electrophoresis |
|
|
Both |
|
|
|
0 |
LDLc SerPl Elph-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Elec; Elect; Electr; Electro; Electrophhrs; Electrophrs; Elp; Elph; Ep; Heart Disease; LDLc; LDL-C; Level; Lipid; Low density lipoprotein cholesterol; Low density lipoprotein cholesterols; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
mg/dL |
|
|
Changed Order_Obs from 'Observation Only' to 'Both' to fit current order use cases. |
0 |
| 49133-2 |
Cholesterol.in VLDL |
MCnc |
Ser/Plas |
Pt |
Qn |
Electrophoresis |
|
ACTIVE |
Cholesterol in VLDL [Mass/volume] in Serum or Plasma by Electrophoresis |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
The VLDL-cholesterol is 15 mg/dl. |
|
|
|
|
|
CHEM |
|
49133-2 |
|
Electrophoresis |
|
|
Observation |
|
|
|
0 |
VLDLc SerPl Elph-mCnc |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; Chol; Choles; Cholest; Cholesterol total; Cholesterols; Elec; Elect; Electr; Electro; Electrophhrs; Electrophrs; Elp; Elph; Ep; Heart Disease; Level; Lipid; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Very low density lipoprotein cholesterols; VLDLc |
2.73 |
2.21 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 49134-0 |
Glucose^2H post dose glucose |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Blood --2 hours post dose glucose |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
200 mg/dl. |
|
|
|
|
|
CHAL |
|
49134-0 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 2h p Glc Bld-mCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p Glc; After; Blood; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p dose; p Glc; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
2.21 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 49135-7 |
Fractional excretion of sodium |
Ratio |
Urine+Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Fractional excretion of sodium [Ratio] in Urine and Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
% |
0.5%. |
|
|
|
|
|
CHEM |
|
49135-7 |
|
|
|
|
Both |
|
|
|
0 |
Fract excret Na Ur+SerPl-Rto |
|
|
|
N |
|
Chemistry; FE Na; FENa; Fract excret Na; Na; Na+; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Ratios; Rto; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UA; UR; Ur+SerPl; Urn |
2.73 |
2.21 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 49136-5 |
Creatine kinase.MB/Creatine kinase.total |
Ratio |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Creatine kinase.MB/Creatine kinase.total [Ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
% |
The relative CK-MB index is 2%. |
|
|
|
|
|
CHEM |
|
49136-5 |
|
|
|
|
Observation |
|
|
|
0 |
CK MB SerPl-Rto |
|
|
|
N |
|
Cardio; Cardiology; Chemistry; CK; CK 2; CK MB; CK-2; CKMB; CK-MB; CPK; Creatine phosphokinase; Heart Disease; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Ratios; Rto; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tot; Totl |
2.73 |
2.21 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 49137-3 |
Hemoglobin |
MCnc |
Urine |
Pt |
SemiQn |
Test strip |
|
ACTIVE |
Hemoglobin [Mass/volume] in Urine by Test strip |
|
MAJ |
DefinitionDescription |
|
|
mg/L |
20 mg/l (teststrip result). |
|
|
|
|
|
UA |
|
49137-3 |
|
Test strip |
|
|
Observation |
|
|
|
0 |
Hgb Ur Strip-mCnc |
|
|
|
N |
|
Blood; Dip stick; Dipstick; Haemoglobin; Hb; Hgb; Level; Mass concentration; Point in time; Random; SmQn; UA; UR; URINALYSIS; Urn |
2.75 |
2.21 |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
